Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results
Nov 8, 2017
PDF 291.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update
Nov 6, 2017
PDF 276.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting
Nov 1, 2017
PDF 329.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple Sclerosis
Oct 31, 2017
PDF 277.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 27, 2017
PDF 284.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 26, 2017
PDF 287.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 16, 2017
PDF 286.8 KB Add to Briefcase
View Summary TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial
Oct 16, 2017
PDF 283.0 KB Add to Briefcase
View Summary TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial
Oct 16, 2017
PDF 281.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development
Oct 5, 2017
PDF 281.4 KB Add to Briefcase
View Summary TG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS)
Sep 29, 2017
PDF 283.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at Upcoming Investor Conferences
Sep 21, 2017
PDF 278.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment
Sep 15, 2017
PDF 281.9 KB Add to Briefcase
View Summary TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial
Sep 5, 2017
PDF 282.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS - ACTRIMS Meeting
Sep 1, 2017
PDF 284.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial
Aug 10, 2017
PDF 281.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results
Aug 9, 2017
PDF 293.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update
Aug 7, 2017
PDF 278.8 KB Add to Briefcase
View Summary TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS)
Aug 1, 2017
PDF 283.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress
Jun 26, 2017
PDF 325.7 KB Add to Briefcase
Showing 1-20 of 214 Page: 1 2 3 4 5 ... 11  Next 20
Add to Briefcase = add release to Briefcase